H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Alnylam (ALNY) to $570 from $500 and keeps a Buy rating on the shares. The firm says the company’s strong commercial execution and pipeline progress drove upward revisions to its 2025 guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma: Strong Commercial Performance and Promising Pipeline Drive Buy Rating
- Alnylam Pharma: Strong Growth Prospects and Transition to Profitability Support Buy Rating
- Alnylam price target raised to $475 from $348 at JPMorgan
- Coinbase downgraded, Spotify upgraded: Wall Street’s top analyst calls
- Alnylam upgraded to Peer Perform from Underperform at Wolfe Research